Ca\textsuperscript{2+} signalling is critical for autoantibody-induced blistering of human epidermis in pemphigus

T. Schmitt,\textsuperscript{1} D.T. Egu,\textsuperscript{1} E. Walter,\textsuperscript{1} A.M. Sigmund,\textsuperscript{1} R. Eichkorn,\textsuperscript{2} A. Yazdi,\textsuperscript{2,3} E. Schmidt,\textsuperscript{4,5} M. Sárdy,\textsuperscript{6} R. Eming,\textsuperscript{7} M. Goebeler\textsuperscript{8} and J. Waschke\textsuperscript{1d}

\textsuperscript{1}Ludwig-Maximilian-Universität München, Anatomische Anstalt, Lehrstuhl Anatomie I – Vegetative Anatomie, Pettenkoferstraße 11, München, D-80336, Germany
\textsuperscript{2}Department of Dermatology, University Medical Center Tübingen, Eberhard Karls-University, Tübingen, Germany
\textsuperscript{3}Department of Dermatology, RWTH Aachen, Aachen, Germany
\textsuperscript{4}Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany
\textsuperscript{5}Department of Dermatology, University of Lübeck, Lübeck, 23562, Germany
\textsuperscript{6}Clinic for Dermatology, Semmelweis University, Budapest, Hungary
\textsuperscript{7}Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany
\textsuperscript{8}Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, 97080, Germany

Correspondence
Jens Waschke.
Email: jens.waschke@med.uni-muenchen.de

Accepted for publication
26 March 2021

Funding sources
The study was supported by the DFG (FOR 2497; to J.W. and A.Y.) and, in part, by structural funds of the Excellence Cluster Precision Medicine in Chronic Inflammation (EXC 2167; to E.S.).

Conflicts of interest
The authors declare they have no conflicts of interest.

Data Availability Statement
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

DOI 10.1111/bjd.20091

Summary

Background Pemphigus is a severe bullous autoimmune skin disease. Pemphigus foliaceus (PF) is characterized by antidesmoglein (Dsg) 1 IgG causing epidermal blistering; mucosal pemphigus vulgaris (mPV) by anti-Dsg3 IgG inducing erosions in the mucosa; and mucocutaneous pemphigus vulgaris (PV) by affecting both, with autoantibodies targeting Dsg1 and Dsg3.

Objectives To characterize the Ca\textsuperscript{2+} flux pathway and delineate its importance in pemphigus pathogenesis and clinical phenotypes caused by different antibody profiles.

Methods Immunoprecipitation, Ca\textsuperscript{2+} flux analysis, Western blotting, immunofluorescence staining, dissociation assays and a human skin ex vivo model were used. Results PV IgG and PF IgG, but neither Dsg3-specific monoclonal antibody (AK23) nor mPV IgG, caused Ca\textsuperscript{2+} influx in primary human keratinocytes. Phosphatidylinositol 4-kinase \(a\) interacts with Dsg1 but not with Dsg3. Its downstream target – phospholipase-C-\(\gamma\)1 (PLC) – was activated by PV IgG and PF IgG but not AK23 or mPV IgG. PLC releases inositol 1,4,5-trisphosphate (IP\(3\)) causing IP\(3\) receptor (IP\(3\)R) activation and Ca\textsuperscript{2+} flux from the endoplasmic reticulum into the cytosol, which stimulates Ca\textsuperscript{2+} release-activated channels (CRAC)-mediated Ca\textsuperscript{2+} influx. Inhibitors against PLC, IP\(3\)R and CRAC effectively blocked PV IgG and PF IgG-induced Ca\textsuperscript{2+} influx; ameliorated alterations of Dsg1 and Dsg3 localization, and reorganization of keratin and actin filaments; and inhibited loss of cell adhesion in vitro. Finally, inhibiting PLC or IP\(3\)R was protective against PV IgG-induced blister formation and redistribution of Dsg1 and Dsg3 in human skin ex vivo.

Conclusions Ca\textsuperscript{2+}-mediated signalling is important for epidermal blistering and dependent on the autoantibody profile, which indicates different roles for signalling complexes organized by Dsg1 and Dsg3. Interfering with PLC and Ca\textsuperscript{2+} signalling may be a promising approach to treat epidermal manifestations of pemphigus.

What is already known about this topic?
\begin{itemize}
  \item Autoantibody-induced Ca\textsuperscript{2+} signalling and activation of phospholipase C in keratinocytes has been reported as the first signalling pathway in pemphigus.
  \item Ca\textsuperscript{2+} influx correlates with the presence of autoantibodies targeting desmoglein (Dsg) 1.
\end{itemize}
The role and exact mechanisms of the Ca\(^{2+}\) signalling pathway and its role in pemphigus pathology are unclear.

**What does this study add?**
- There is an important role of the phospholipase C/Ca\(^{2+}\) signalling pathway in the pathogenesis of pemphigus.
- Relevant signal components of the Ca\(^{2+}\) pathway are characterized in detail.
- Dsg1 and Dsg3 are found to interact with signalling molecules, organizing signalling complexes that differ with respect to the presence of phosphatidylinositol 4-kinase α, the most upstream activator of the Ca\(^{2+}\)-influx pathway, assigning different roles to Dsg1- and Dsg3-mediated signalling.

**What is the translational message?**
- Current therapies for pemphigus have a delayed onset of action. Rapidly effective therapeutic approaches that directly stabilize desmosomal adhesion are desirable.
- While targeting the Ca\(^{2+}\) flux is problematic, the role of phospholipase C in the influx identifies this molecule as a potential target for specific molecular therapy approaches.
- Elucidating the mechanism of Dsg1-dependent regulation of Ca\(^{2+}\) influx in keratinocytes helps us to understand the different blistering patterns and the phenotypic variability seen in pemphigus.

Bullous autoimmune diseases of the pemphigus group cause disruption of the skin and/or mucosal barrier. The main variants of pemphigus are mucosal pemphigus (mPV), which affects the mucosa only; mucocutaneous pemphigus vulgaris (PV), which also causes epidermal blistering; and the less severe variant, pemphigus foliaceus (PF), where blistering is restricted to the epidermis.\(^1\),\(^2\) Pemphigus may lead to severe complications and high mortality if untreated.\(^3\) Current first-line treatments are systemic high-dose corticosteroids combined with immunosuppressants or rituximab; however, these have an delayed onset of action and may cause severe adverse reactions.\(^4\) Other treatment options include intravenous IgG or immunoadsorption, which also have drawbacks, such as the limited availability of donor IgG,\(^5\) general immunosuppression or short-term effectiveness.\(^2\),\(^3\),\(^6\) Therefore, rapid-acting and effective treatment options that promote the stabilization of desmosomal adhesion in keratinocytes until the formation of new autoantibodies is inhibited are highly desirable.\(^7\) The main goals of current research remain a better understanding of the pathophysiology of pemphigus and the identification of more specific treatment options.

Pemphigus is caused primarily by autoantibodies against the desmosomal cadherins desmoglein (Dsg) 1 for PF, Dsg3 for mPV, and Dsg1 and Dsg3 for PV.\(^1\),\(^2\),\(^8\) however, it is also caused by antibodies targeting other proteins.\(^9\),\(^10\) Desmosomes are robust adhesive cell–cell contacts,\(^11\) in which desmosomal cadherins are connected to plaque proteins, which, in turn, link the desmosome to the keratin cytoskeleton.\(^12\),\(^13\) Desmosomes provide mechanical stability and also partake in cell signalling.\(^14\) In pemphigus, loss of desmosomal adhesion is caused by both direct inhibition of cadherin interaction and intracellular signalling.\(^7\),\(^15\)–\(^18\)

It is well known that the clinical pemphigus phenotypes correlates with autoantibody profiles. Anti-Dsg1 IgG modulates specific signalling pathways and is required for epidermal loss of adhesion and blistering.\(^1\),\(^19\),\(^20\) In human keratinocytes, PV IgG has been demonstrated to activate phospholipase C-γ1 (PLC), generating inositol 1,4,5-trisphosphate (IP3), and induce Ca\(^{2+}\) influx.\(^21\) PF IgG induces Ca\(^{2+}\) influx even under conditions when Dsg2 or Dsg3 were depleted, indicating a Dsg1-dependent mechanism.\(^22\) In line with this, an interaction between Dsg1 and phosphatidylinositol 4-kinase α (PI4K), an upstream kinase of PLC,\(^23\) had been predicted.\(^24\) Further downstream, IP3 is well established to activate the IP3 receptor (IP3R), which releases Ca\(^{2+}\) from the endoplasmic reticulum (ER) into the cytosol.\(^25\) Finally, cytosolic Ca\(^{2+}\) activates protein kinase C (PKC),\(^26\) which has been shown to be important in pemphigus IgG-induced loss of keratinocyte adhesion and skin blistering, resulting in depletion of Dsg3, keratin retraction and the loss of cell adhesion in vitro.\(^13\),\(^27\)–\(^31\) However, the exact mechanisms involved in the Ca\(^{2+}\) pathway and its pathogenic role in pemphigus remain unknown and were therefore investigated in this study.

**Materials and methods**

**Cell culture**

For in vitro experiments, primary normal human epidermal keratinocytes (NHEK) in passage 2–6 or HaCaT cells were used and cultured as previously described.\(^31\) Cells were
incubated with vehicle or mediators at a dilution of 1 : 50 in dimethyl sulfoxide (DMSO) for 1 h before IgG treatment. See Table 1 for details of the PV IgG used in this study.

**Immunostaining**

Cells were grown on glass coverslips and fixed with 2% paraformaldehyde for 5 min or in ethanol (at –20 °C) shaken on ice for 30 min and acetone (at –20 °C) for 3 min. Paraformaldehyde-fixed cells were permeabilized with 1% Triton X-100 in phosphate-buffered saline (PBS) for 5 min and blocked with 3% bovine serum albumin (BSA) and 1% normal goat serum in PBS for 30 min. Primary antibodies were applied overnight at 4 °C. Cy3-coupled goat antirabbit/mouse/human secondary antibodies (Dianova, Hamburg, Germany) were incubated with Alexa Fluor™ 488 phalloidin (Life Technologies, Carlsbad, CA, USA) for 1 h and with 4',6-diamidino-2-phenylindole (DAPI) 1 : 10 000 for 15 min. The cover slips were mounted with n-propyl gallate 2% and evaluated with a SP5.II confocal microscope equipped with a × 63 NA 1.4 PL APO objective (Leica, Wetzlar, Germany). After heating to 60 °C for 30 min, skin slices were processed in a similar way, except that they were permeabilized for 1 h. Samples were washed three times with PBS between each step of the staining protocol except between the transition from ethanol to acetone.

**Ratiometric intracellular Ca²⁺ measurements**

Fura-2-acetoxymethyl ester (Thermo Fisher Scientific, Waltham, MA, USA) was used to measure intracellular Ca²⁺ in real time, as described previously. For each independent experiment, the signals from eight of 15 randomly selected cells were evaluated (occasional nonresponding cells were not included; very rare oscillating cells and weak responders were included, n = 4).

**Co-immunoprecipitation**

NHEKs were cultured in T75 flasks, washed once with PBS + 10 g L⁻¹ ethylenediaminetetraacetic acid and twice with PBS. For cell lysis, 1 mL Ca²⁺-free PBS with 68-5 mmol L⁻¹ half-normal NaCl + 1% Triton™ X-100 + 1% nonoxinol-40 + 0.1% sodium dodecyl sulfate (SDS) + Complete™ (Merck, Kenilworth, NJ, USA) was used, shaking for 15 min on ice. Buffer without SDS, 0.5% Triton X-100 and 0.1% nonoxinol-40 was used for washing. The cells were mechanically detached and sheared with a 5 mL syringe and 10 G needle (B. Braun, Melsungen, Germany) 10 times. The resulting suspension was centrifuged at 4 °C for 15 min at 17 949 g, and the pellet was removed. The amount of protein was determined with a commercial Pierce BCA protein assay kit (Thermo Fisher Scientific). The supernatant was added to buffer-washed agarose G beads (Millipore, Burlington, MA, USA) adding about 600–1000 µg protein. After 1.5 h on a rotator, the beads were removed via centrifugation for 2 min at 4 °C (6797 g) and the supernatant was mixed with 1.5 µl antibody or normal rabbit IgG, 1 mmol L⁻¹ Ca²⁺ and 0.5 mmol L⁻¹ Mg²⁺, and rotated for 3 h. The mixture was added to washed beads and rotated at 4 °C overnight. The beads were washed three times (1 min at 4 °C, 959 g). Proteins were released from the beads by washing three times with 27 µl Lämmli buffer at 95 °C, and beads were then removed by centrifugation (5 min at 4 °C; 6797 g).

**Cell lysis, gel electrophoresis and Western blotting**

Cells were cultured in 24-well plates. Lysates were fractioned into a soluble and insoluble fraction using Triton extraction buffer. Lysis electrophoresis and Western blotting were performed as described previously. Antibodies were incubated overnight at 4 °C in 5% BSA in Tris-buffered saline with Tween 20 1 : 1000, except for anti-pPKCa (1 : 20 000).

**Dispase-based dissociation assay**

Dissociation assays were performed as described previously, subjecting the cells to IgG for either 2 h or 24 h.

**Human skin samples**

Skin biopsies from donors who had been deceased for < 24 h were used. Each piece of epidermis (~4 cm²) was excised from the shoulder region and divided into ~1 cm² pieces. Either 50 µL U-73122 (4 µmol L⁻¹), Xest (2 µmol L⁻¹) in DMSO/PBS 1 : 50 or vehicle were injected intraepidermally, followed by floating incubation as described previously. After 1 h incubation, either PV2 or IgG control was injected. Injections were performed as described previously.

**Haematoxylin and eosin staining**

Samples were embedded in tissue freezing medium (Leica Biosystems, Nüßloch, Germany) and 7-µm sections were done using a CryoStar™ NX70 Kryostat (Thermo Fisher Scientific). The resulting sections were stained with haematoxylin and eosin according to standard protocols. For morphometric analysis, images were captured at × 200 magnification using a light DMI8 microscope (Leica).
Statistical analysis

Data were analysed in Excel (Microsoft, Redmond, WA, USA) and compared using a one- or two-way ANOVA followed by a Bonferroni post-hoc test (for Gaussian-distributed samples) using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Significance was assumed with a P-value of ≤ 0.05. Data are shown as mean (SEM).

Results

Pemphigus IgG induces desmoglein 1-dependent Ca\textsuperscript{2+} flux via inositol 1,4,5-triphosphate receptor and Ca\textsuperscript{2+} release-activated channel in vitro

Firstly, we confirmed that the main components of the Ca\textsuperscript{2+} pathway are expressed in human keratinocytes. As outlined...
above, IP3R redistributes Ca2+ from the ER to the cytosol, and low ER Ca2+ activates stromal interaction molecule 1 (STIM1) in the ER membrane. Secondly, STIM1 contacts calcium release-activated calcium channel protein 1 (ORAI1) to form the Ca2+ release-activated channel (CRAC).33 to replenish the Ca2+ store in the ER.34,35 We saw that IP3R and ORAI1 were evenly distributed in all epidermal layers, whereas STIM1 was more prominent in the granular layer (Figure 1a). Similarly to previous studies,31 PV and PF IgG (Table 1), but not IgG from healthy volunteers or AK23 or mPV IgG, increased intracellular Ca2+ in NHEK cells (Figure 1b and Figure S1a; see Supporting Information). mPV IgG was used in addition to AK23, to avoid clonal differences being overlooked, which has been reported previously.36 In agreement with previous reports,22,31 the Ca2+ flux correlated with the presence of anti-Dsg1 IgG. The inhibition of CRAC, IP3R, PLC or PI4K stopped the Ca2+ influx caused by pemphigus IgG (Figure 1b and Figure S1a). Co-immunoprecipitation demonstrated that PI4K interacts with Dsg1 but not with Dsg3. In contrast, the downstream targets of PI4K, such as activated phosphorylated PKC and PLC, as well as p38 mitogen-activated protein kinase (MAPK), are well known to be involved in the pathogenesis of pemphigus,32,37 and are part of both Dsg1- and Dsg3-orchestrated complexes (Figure 1c, d and Figure S1b). This is important because, so far, only the interaction of p38 MAPK with Dsg3 has been shown.38,39 PV IgG and PF IgG, but not AK23 or mPV IgG, induced phosphorylation of PLC (Figure 1e, f). Taken together, these data indicate the existence of a Dsg1-specific signalling complex, which, in response to the binding of pemphigus IgG, can initiate a Ca2+ flux-dependent pathway.

**Inhibition of Ca2+ flux is protective against anti-desmoglein 1 IgG-induced pathogenic effects in vitro and human skin ex vivo**

Next, we evaluated the role of Ca2+ signalling in the loss of keratinocyte adhesion in vitro. PV IgG caused loss of keratinocyte adhesion in dispase-based dissociation assays in NHEKs after 2 h and 24 h and PF IgG after 24 h (Figure 2 and Figure S2; see Supporting Information). mPV did not affect adhesion in NHEKs but was effective in HaCaT cells (Figure S2). Treatment with inhibitors against PI4K, PLC, IP3R or CRAC added 1 h before pemphigus autoantibodies effectively blocked the cell sheet fragmentation after 2 h and 24 h. After 24 h, inhibition of PLC even reduced the pathogenic effect of AK23 on cell adhesion (Figure 2 and Figure S2).

To evaluate the underlying mechanisms, immunostaining for desmosomal and cytoskeletal components was employed. After being subjected to PV IgG for 24 h, immunostaining for Dsg1 and Dsg3 showed a fragmented pattern at cell borders and partially relocated to the cytosol (Figure 3a and Figure S3a–c; see Supporting Information). For PF IgG and mPV IgG the localization of Dsg1 and Dsg3, respectively, was affected. Treatment with inhibitors for PI4K, PLC, IP3R or CRAC ameliorated the pathogenic effects. In contrast to PV IgG-induced fragmentation of Dsg3 staining, mPV IgG-induced fragmentation of Dsg3 staining was not affected (Figure S3).

In addition to reorganization of desmosomal cadherins, keratin filaments retracted from the cell borders after 24 h of pemphigus IgG treatment (except mPV2). All inhibitors ameliorated the effect (Figure 3b and Figure S3d). Similarly,
Cortical F-actin was disrupted, which was ameliorated by all inhibitors (Figure 3 and Figure S3). Interestingly, F-actin staining often appeared more pronounced after PLC inhibition (Figure 3 and Figure S3).

Finally, we tested whether interference with Ca²⁺ signalling was effective in ameliorating the pathogenic effects of PV IgG in intact human skin *ex vivo*. AK23 and mPV IgG were omitted as, in our model—similar to the situation in patients with pemphigus—both have been shown to cause mucosal blistering only and not epidermal blistering.³²,⁴⁰ Human skin samples subjected to PV IgG *ex vivo* showed typical suprabasal blistering with a characteristic tombstone pattern of basal keratinocytes (Figure 4 and Figure S4; see Supporting Information). PV IgG was not only enriched at the blistering sites, but was also detectable in unaffected regions, where it was located at cell borders (Figure S4a). Similarly to cultured keratinocytes Dsg1 and Dsg3 staining was fragmented and redistributed to the cytosol (Figure 4c and Figure S4b), while F-actin staining was almost abolished at blistering sites (Figure 4d). Importantly, blistering was completely blocked by inhibition of PLC or IP₃R (Figure 4 and Figure S4).

**Discussion**

The data presented here demonstrate, for the first time, that Dsg1-dependent Ca²⁺ influx plays a central role in the epidermal pathology of pemphigus. Most importantly, inhibition of Ca²⁺ signalling blocked pemphigus IgG-induced loss of keratinocyte adhesion *in vitro* and blistering in human skin *ex vivo*. PV IgG- and PF IgG-containing autoantibodies against Dsg1 induced PLC activation and Ca²⁺ influx, which were required for the reorganization of Dsg1 and Dsg3, as well as of the keratin and actin cytoskeleton (Figure 5). These observations are in line with early reports demonstrating that PLC-mediated Ca²⁺ influx is the earliest signalling event in pemphigus.²¹ The second novelty of this study is that Dsg1 and Dsg3 form signalling complexes in which they associate with several molecules involved in pemphigus pathogenesis such as PLC, PKC and p38 MAPK. Previously, only the association of p38 MAPK with Dsg3 has been demonstrated.³⁸

PLC appears to be one of the most promising pharmaceutical targets of this pathway. For interfering with PV IgG-induced loss of cell adhesion *in vitro*, inhibition of PLC was most efficient. After 24 h of incubation, loss of adhesion was completely abolished. Moreover, loss of adhesion induced by AK23, which did not cause Ca²⁺ influx or enhance baseline PLC activity, was significantly ameliorated by inhibiting PLC. This may indicate that PLC targets such as PKC might be activated by baseline PLC activity. Alternatively, PLC may regulate other targets involved in pemphigus pathogenesis such as p38 MAPK or actin remodelling via Ras homolog family member A.⁴¹,⁴² Finally, it has to be noted that pemphigus IgG against thyroid peroxidase and other targets might also be able to activate PLC isoforms and Ca²⁺ flux,⁹,³⁴,⁴³ which also suggests that inhibition of PLC may be effective to treat pemphigus.

The data presented here suggest that PLC-mediated Ca²⁺ influx is dependent on Dsg1 (Figure 5). In line with this, PV IgG and PF IgG induced PLC phosphorylation and Ca²⁺ influx, whereas AK23 and mPV IgG, both of which target Dsg3 but not Dsg1, did not trigger this pathway. This may be explained...
by the fact that signalling molecules such as p38 MAPK, PLC and PKC\(\alpha\) form signalling complexes with both Dsg1 and Dsg3. In contrast, PI4K\(\alpha\), the most upstream kinase of this pathway, is associated with Dsg1 only. This may also explain why Dsg3 localization is affected by the Ca\(^{2+}\) flux pathway, although autoantibodies binding to Dsg3 cannot initiate signalling. We noted that mPV IgG with antibodies against Dsg3 but not Dsg1 were insufficient to cause the loss of adhesion in primary keratinocytes, despite causing severe fragmentation of Dsg3 staining. This reflects the situation in patients where the unaffected skin of mucosal PV also displays severe fragmentation of Dsg3 localization,\(^45,46\) and the ex vivo skin model where mPV IgG, similar to AK23, does not cause blistering.\(^32\) In line with this, fragmentation of Dsg3 staining induced by PV IgG, but not by mPV IgG, was ameliorated by inhibiting the Ca\(^{2+}\) flux pathway, indicating that different mechanisms are involved in mucosal PV. Similarly, it was reported that inhibition of p38 MAPK was protective against blistering in skin but not in mucosa.\(^47\) Nevertheless, the mPV IgG fraction used in our study caused significant cell sheet fragmentation in HaCaT cells, indicating that primary keratinocytes better reflect the role of DSG3 for keratinocyte adhesion.

PKC isoforms are one of the primary downstream targets of the Ca\(^{2+}\) pathway. PKC affects cell adhesion in several ways.

|                  | Maximum relative cleft length | Total relative cleft length | Maximum cleft length (µm) | Total cleft length (µm) | No. of blisters |
|------------------|-------------------------------|-----------------------------|--------------------------|-------------------------|----------------|
| Vehicle + IgG    | 0                             | 0                           | 0                        | 0 (0)                   | 0              |
| U-73122 + IgG    | 0                             | 0                           | 0                        | 0 (0)                   | 0              |
| Xest + IgG       | 0                             | 0                           | 0                        | 0 (0)                   | 0              |
| Vehicle + PV2    | 22.4%                         | 14 (2)%                     | 1178.06                  | 700.44 (216.64)         | 1–5            |
| U-73122 + PV2    | 0                             | 0                           | 0                        | 0 (0)                   | 0              |
| Xest + PV2       | 0                             | 0                           | 0                        | 0 (0)                   | 0              |

Figure 4 (a) Quantitative evaluation of blister formation in human skin slices ex vivo. (b) Representative microscopic images of haematoxylin and eosin staining of human skin slices after 24 h IgG treatment (n > 3). (c) Immunostaining of desmoglein (Dsg) 1 (mouse monoclonal antibody; Progen, Heidelberg, Germany) in human skin slices after pemphigus vulgaris (PV) 2 treatment. (d) F-actin staining in human skin slices after PV2 treatment. Each set of images shows a × 4 zoom of the blister roof and bottom. Green arrows indicate missing staining at the cell border; white arrows indicate the remaining basal cells (tomblasting) with reduced staining (n = 3, scale bar 50 µm).
The stability of newly formed desmosomes is dependent on extracellular Ca^{2+}. After several days, desmosomes become hyperadhesive and Ca^{2+}-independent. In this state, they are also less sensitive to PV IgG. Inhibiting PKC results in a rapid transformation from Ca^{2+}-dependent to Ca^{2+}-independent desmosomes. Upon PV IgG treatment PKC has been reported to translocate to the desmosomal plaque. Cytoskeletal components such as keratin 8 and 18 are also substrates of PKC, possibly affecting keratin filament retraction. Similarly, PKC affects the actin cytoskeleton, mostly causing disassembly and reduced anchorage, and possibly modulates desmosome turnover via the actin-binding adducin.

However, results concerning the role of PKC in the regulation of desmosomes are often contradictory. Specifically, inhibiting PKCβ was not sufficient to prevent fragmentation in vitro. In line with this, the targets of PKCβ specifically seem to be of little relevance for cell adhesion. Inhibiting other PKCs ameliorated PV IgG-induced loss of adhesion in vitro but were not sufficient to block blistering in human skin ex vivo. However, it has to be borne in mind that there are many isoforms of PKC and at least three species are activated by different mechanisms, including diacylglycerol (DAG) and cytoplasmic Ca^{2+} for calcium-dependent PKC (cPKC), DAG for novel (nPKC) and translocation for atypical, respectively. At least cPKCs and nPKCs are downstream targets of PLC and thus may be activated in response to autoantibodies in pemphigus.

Taken together, the data from this study support the hypothesis that PV pathology is dependent on patients’ autoantibody profiles, with different anti-Dsg1/Dsg3 ratios and target epitopes playing an important role by eliciting different cellular responses. Similarly, different signalling responses to PV IgG, PF IgG and AK23 have been previously reported to be dependent on the presence of autoantibodies targeting Dsg1, Dsg3 or desmocollin. Therefore, the data presented here help to explain why autoantibodies against Dsg1 but not against Dsg3 are required for epidermal involvement and why the phenotypes of PF, PV and mPV are clinically different. These insights may help to develop novel Dsg1-specific treatment strategies for pemphigus.

Acknowledgments

We thank Silke Gotschy, Martina Hitzenbichler, Sabine Mühlslmer and Nadine Albrecht for their excellent technical assistance; and Jessica Plewa, Michael Becker and Axel Unverzagt for their assistance with the body donors received by the Institute of Anatomy and Cell Biology, Ludwig-Maximilian-Universität München, Germany. The body donors had given written informed consent for use of tissue samples for research purposes (positive ethics vote project no. 249-12). Normal human epidermal keratinocytes were generated at the Universität-Hautklinik Tübingen, in accordance with the Declaration of Helsinki (ethical approval: 547/2011BO2). All pemphigus...
vulgaris samples were received from patients who had given written informed consent. Positive ethics votes were given by the University Hospital Lübeck (Az 12-178; for PV1), University Hospital Budapest (249-12; for PV2), University Hospital Marburg (Studie 20/14, PV3, PF) and Faculty of Medicine, University of Würzburg (Az.:#159/06; mPV1 and 2). Open Access funding enabled and organized by Projekt DEAL.

References

1. Kasperkiewicz M, Ellebrecht CT, Takahashi H et al. Pemphigus. Nat Rev Dis Primers 2017; 3:17026.
2. Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394:882–94.
3. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996; 34:465–3.
4. Schmidt E, Sticherling M, Sárdy M et al. S2k-leitlinie zur therapie des pemphigus vulgaris/foliate und des bullösen pemphigoids: 2019 update. J Dtsch Dermatol Ges 2020; 18:516–27.
5. Bayry J, Kazatchkine MD, Kaveri SV. The desmosome and pemphigus. Histochem Cell Biol 2004; 121:99–107.
6. Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Rev 2018; 286:255–70.
7. Burnmester IAK, Flaswinkel S, Thies C-S et al. Identification of novel therapeutic targets for blocking acantholysis in pemphigus. Br J Pharmacol 2020; 177:5114–30.
8. Armaci M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012; 132:776–84.
9. Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol 2018; 9:1190.
10. Saadu T, Sinha AA. Autoantibody signalling in pemphigus vulgaris: development of an integrated model. Front Immunol 2018; 9:692.
11. Waschke J. The desmosome and pemphigus. Histochem Cell Biol 2008; 130:21–54.
12. Kröger C, Loschke F, Schwarz N et al. Keratins control intercellular adhesion involving PKC-δ-mediated desmoplakin phosphorylation. J Cell Biol 2013; 201:681–92.
13. Dehner C, Rötzer V, Waschke J, Spindler V. A desmoplakin point mutation with enhanced keratin association ameliorates pemphigus vulgaris autoantibody-mediated loss of cell cohesion. Am J Pathol 2014; 184:2528–36.
14. Waschke J, Spindler V. Desmosomes and extradesmosomal adhesive signaling contacts in pemphigus. Med Res Rev 2014; 34:1127–43.
15. Heupel W-M, Zillikens D, Drenckhahn D, Waschke J. Pemphigus vulgaris IgG directly inhibits desmoglein 3-mediated transinteraction. J Immunol 2008; 181:1825–34.
16. Vielmuth F, Waschke J, Spindler V. Loss of desmoglein binding is not sufficient for keratinocyte dissociation in pemphigus. J Invest Dermatol 2015; 135:3068–77.
17. Ishii K, Yoshioka K, Stanley JR et al. Pemphigus vulgaris and foliate IgG autoantibodies block desmoglein-3 mediated desmosome interaction. J Invest Dermatol 2020; 140:1911–26.
18. Kitajima Y, Aoyama Y, Seishima M. Transmembrane signaling for adhesion regulation of desmosomes and hemidesmosomes, and for cell-detachment induced by pemphigus IgG in cultured keratinocytes: involvement of protein kinase C. J Investig Dermatol Symp Proc 1999; 4:137–44.
19. Spindler V, Waschke J. Pemphigus – a disease of desmosome dysfunction caused by multiple mechanisms. Front Immunol 2018; 9:136.
20. Mahoney MG, Wang Z, Rothenberger K et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103:461–8.
21. Isaki C, Seishima M, Yamada T et al. Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DM1-cells, a squamous cell carcinoma line. J Invest Dermatol 1995; 105:329–33.
22. Walter E, Vielmuth F, Wanuske M-T et al. Role of Dsg1- and Dsg3-mediated signaling in pemphigus autoantibody-induced loss of keratinocyte cohesion. Front Immunol 2019; 10:1128.
23. Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev 2013; 93:1019–137.
24. Huttlin EL, Bruckner RJ, Paolo JA et al. Architecture of the human interactome defines protein communities and disease networks. Nat 2017; 545:505–9.
25. Streb H, Irvine RF, Berridge MJ, Schulz I. Release of Ca 2+ from a nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1,4,5-trisphosphate. Nature 1983; 306:67–9.
26. Osada K, Seishima M, Kitajima Y. Pemphigus IgG activates and translocates protein kinase C from the cytosol to the particulate/cytoskeleton fractions in human keratinocytes. J Invest Dermatol 1997; 108:482–7.
27. Cirillo N, Lanza A, Prime SS. Induction of hyper-adhesion attenuates autoimmune-induced keratinocyte cell-cell detachment and processing of adhesion molecules via mechanisms that involve PKC. Exp Cell Res 2010; 316:580–92.
28. Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol 1999; 112:67–71.
29. Spindler V, Endlich A, Hohlbein E et al. The extent of desmoglein 3 depletion in pemphigus vulgaris is dependent on Ca 2+ -induced differentiation. Am J Pathol 2011; 179:1905–16.
30. Sánchez-Carpintero I, España A, Pelacho B et al. In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades. Br J Dermatol 2004; 151:565–70.
31. Walter E, Vielmuth F, Rotkopf L et al. Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus. Sci Rep 2017; 7:3579.
32. Egu DT, Walter E, Spindler V, Waschke J. Inhibition of p38 MAPK signalling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis. Br J Dermatol 2017; 177:1612–8.
33. Wang Y, Deng X, Hewavitharana T et al. Stim, ORAI and TRPC channels in the control of calcium entry signals in smooth muscle. Clin Exp Pharmacol Physiol 2008; 35:1127–33.
34. Yeung PS-W, Yamashita M, Prakriya M. Pore opening mechanism of CRAC channels. Cell Calcium 2017; 63:14–9.
35. Bird GS, Hwang S-Y, Smyth JT et al. STIM1 is a calcium sensor specialized for digital signaling. Curr Biol 2009; 19:1724–9.
36. Yamamoto Y, Aoyama Y, Shu E et al. Anti-desmoglein 3 (Dsg3) monoclonal antibodies deplete desmosomes of Dsg3 and differ in their Dsg3-depleting activities related to pathogenicity. J Biol Chem 2007; 282:17866–76.
37. Berkowitz P, Hu P, Warren S et al. p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc Natl Acad Sci U S A 2006; 103:12855–60.
38. Spindler V, Rötzer V, Dehner C et al. Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. J Clin Invest 2013; 123:800–11.
39 Hartlieb E, Rötzler V, Radeva M et al. Desmoglein 2 compensates for desmoglein 3 but does not control cell adhesion via regulation of p38 mitogen-activated protein kinase in keratinocytes. J Biol Chem 2014; 289:17043–53.

40 Egu DT, Kugelmann D, Waschke J. Role of PKC and ERK signaling in epidermal blistering and desmosome regulation in pemphigus. Front Immunol 2019; 10:2883.

41 Berkowitz P, Hu P, Liu Z et al. Plakophilin-1 protects keratinocytes from pemphigus vulgaris IgG by forming calcium-dependent desmosomes. J Biol Chem 2005; 280:23778–84.

42 Waschke J, Spindler V, Bruggeman P et al. Inhibition of Rho A activity causes pemphigus skin blistering. J Cell Biol 2006; 175:723–7.

43 Seiffert-Sinha K, Khan S, Artwood K et al. Anti-thyroid peroxidase reactivity is heightened in pemphigus vulgaris and is driven by human leukocyte antigen status and the absence of desmoglein reactivity. Front. Immunol. 2018; 9:625.

44 Sinha AA, Sajda T. The evolving story of autoantibodies in pemphigus vulgaris: development of the “super compensation hypothesis”. Front. Immunol 2018; 5:218.

45 Oktarina DAM, van der Wier G, Dieck GFH et al. Inhibition of PKC and the regulation of the actin cytoskeleton. Cell Signal 2006; 18:276–84.

46 van der Wier G, Pas HH, Kramer D et al. Smaller desmosomes are seen in the skin of pemphigus patients with anti-desmoglein 1 antibodies but not in patients with anti-desmoglein 3 antibodies. J Investig Dermatol 2014; 134:2287–90.

47 Egu DT, Signum AD, Schmidt E et al. A new ex vivo human oral mucosa model reveals that p38 MAPK inhibition is not effective in preventing autoantibody-induced mucosal blistering in pemphigus. Br J Dermatol 2020; 182:987–94.

48 Watt FM, Mathey DL, Garrod DR. Calcium-induced reorganization of desmosomal components in cultured human keratinocytes. J Cell Biol 1984; 99:2211–5.

49 Kimura TE, Merritt AJ, Garrod DR. Calcium-independent desmosomes of keratinocytes are hyper-adhesive. J Invest Dermatol 2007; 127:775–81.

50 Hobbs RP, Green KJ. Desmoplakin regulates desmosome hyperadhesion. J Investig Dermatol 2012; 132:482–5.

51 Tucker DK, Stahley SN, Kowalczyk AP. Plakophilin-1 protects keratinocytes from pemphigus vulgaris IgG by forming calcium-independent desmosomes. J Investig Dermatol 2014; 134:1033–43.

52 Yano T, Tokui T, Nishi Y et al. Phosphorylation of keratin intermediate filaments by protein kinase C, by calmodulin-dependent protein kinase and by cAMP-dependent protein kinase. Eur J Biochem 1991; 197:281–90.

53 Bordeleau F, Galameau L, Gilbert S et al. Keratin 8/18 modulation of protein kinase C-mediated integrin-dependent adhesion and migration of liver epithelial cells. Mol Biol Cell 2010; 21:1698–713.

54 Kang J-H, Toita R, Kim CW, Katayama Y. Protein kinase C (PKC) isozyme-specific substrates and their design. Biotechnol Adv 2012; 30:1662–72.

55 Larsson C. Protein kinase C and the regulation of the actin cytoskeleton. Cell Signal 2006; 18:276–84.

56 Rötzler V, Breit A, Waschke J, Spindler V. Adducin is required for desmosomal cohesion in keratinocytes. J Biol Chem 2014; 289:14925–40.

57 vars M, España A, Alzuguren P et al. The involvement of ADAM10 in acantholysis in mucocutaneous pemphigus vulgaris depends on the autoantibody profile of each patient. Br J Dermatol 2020; 182:1194–204.

**Supporting Information**

Additional Supporting Information may be found in the online version of this article at the publisher’s website:

**Figure S1** (a) Ca$^{2+}$ flux measurements upon IgG addition. (b) Co-immunoprecipitation experiments using normal human epidermal keratinocytes.

**Figure S2** (a) Representative dissociation assay results after treatment with PV3 for 2 h. (b) Quantification of dissociation assay results after treatment with PV3 for 2 h. (c) Representative dissociation assay results after treatment with PV3 for 24 h. (d) Quantification of dissociation assay results after treatment with PV3 for 24 h.

**Figure S3** (a) Immunostaining of desmoglein (Dsg) 3 in normal human epidermal keratinocyte (NHEK) cells after PV1 treatment for 24 h. (b) Immunostaining of Dsg3 in NHEK cells after PV1 treatment for 24 h. (c) Immunostaining of Dsg1 in NHEK cells after PV3 treatment for 24 h. (d) Immunostaining of the cytofilament filaments in NHEK cells after PV3 treatment for 24 h.

**Figure S4** (a) Immunostaining of PV2 with goat anti-human IgG Cy3. (b) Immunostaining of desmoglein 3 in human skin slices after PV2 treatment.